With a market cap of $9.3 billion, Moderna, Inc. (MRNA) is a biotechnology company specializing in the development of messenger RNA (mRNA) therapeutics and vaccines. Known for its COVID-19 vaccine ...

Moderna also hopes that combining the shots will help improve vaccine rates. Poland, however, is not sure people will like ...

Senior leaders at the FDA began pushing Moderna and Pfizer to file for full, formal approval of their COVID vaccines for ...

The trial, which involved more than 8,000 adults 50 and older, found that antibody levels generated by the new vaccine were about 20% to 40% higher than getting the shots apart, with the exception of ...

Stat: Vinay Prasad's FDA Speech: Praises Staff, Embraces Evidence In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his admiration for agency ...

Moderna and Benchling are focused on three priorities with this digital transformation: consolidating systems to create a seamless experience for scientists, automating scientific workflows, and ...

A combination shot for flu and COVID-19 using messenger RNA generated antibodies in a study, but U.S. government regulators ...

The U.S. Food and Drug Administration said on Wednesday it will hold a meeting of experts on May 22 to discuss COVID-19 ...

Learn more about whether Moderna, Inc. or Avidity Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Moderna is being audited by the PMCPA after yet again being found to have brought discredit on the pharma industry, putting the company on a path that could lead to its suspension from U. | Moderna is ...

In a study published in the Journal of the American Medical Association, researchers from Moderna reported that the new combo ...